Table 1

Clinical characteristics of the study groups

CharacteristicsACEI/ARB (n=134)Non-ACEI/ARB (n=116)P value
Age (years)36.6±6.137.3±6.00.62
Gender (male/female)77/5763/530.74
Admission systolic blood pressure (mm Hg)138±23126±210.52
Admission diastolic blood pressure (mm Hg)78±1472±130.29
Smoking10 (7.3)11 (9.2)0.45
Laboratory data
White cell count (×109/L)7.8±2.67.4±2.30.54
Hemoglobin (mg/dL)23,59± 3.0621.91±3.060.60
Hematocrit40.2±539.6±50.59
Platelets, (×109/L)196±46207±640.38
Sedimentation45.8±27.847.3±26.70.88
Glucose (mg/dL)90.8±9.288.7±9.20.32
Blood urea nitrogen (mg/dL)14.1±5.214.2±5.60.24
Creatinine (mg/dL)0.95±0.60.81±0.180.45
Uric acid (mg/dL)6.1±1.94.9±1.30.48
Lactate dehydrogenase (U/L)478±276442±1750.32
AST (IU/L)25±10.624.5±9.50.82
ALT (IU/L)33±1934±19.50.84
C reactive protein (mg/dL)38±7940±840.92
Fibrinogen (mg/L)549±138521±1520.45
D-dimer (mg/L)1.14±2.11.24±2.30.81
Creatine kinase (mg/dL)114±47106±460.40
CK-MB (mg/dL)0.88±0.510.72±0.430.82
Troponin (µg/mL)13.1±4014.3±430.93
ProBNP (pg/mL)56±3256.7±420.78
Antihypertensive medications, n (%)
Calcium channel blockers45 (33.2)28 (24.3)0.17
Beta blockers43 (31.5)32 (27.2)0.41
Other medications, n (%)
Anticoagulant therapy7 (4.6)8 (6.9)0.31
Aspirin45 (32.9)34 (29.5)0.09
Furosemide9 (7.2)5 (4.4)0.30
Statins32 (23.2)18 (15.8)0.28
Left ventricular ejection fraction (%)58±1255±100.25
Metabolic equivalents7±38±40.18
  • ACEI, ACE inhibitor; ALT, alanine transaminase; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase; BNP, brain natriuretic peptide; CK-MB, creatine kinase myocardial band.